amphotericin-b and Water-Electrolyte-Imbalance

amphotericin-b has been researched along with Water-Electrolyte-Imbalance* in 3 studies

Reviews

1 review(s) available for amphotericin-b and Water-Electrolyte-Imbalance

ArticleYear
[Side effects of systemic antimycotics].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2003, Volume: 48, Issue:8

    Topics: Amphotericin B; Antifungal Agents; Chills; Fever; Fluconazole; Humans; Itraconazole; Meta-Analysis as Topic; Mycoses; Nausea; Vomiting; Water-Electrolyte Imbalance

2003

Trials

1 trial(s) available for amphotericin-b and Water-Electrolyte-Imbalance

ArticleYear
N-acetyl cysteine in prevention of amphotericin- induced electrolytes imbalances: a randomized, double-blinded, placebo-controlled, clinical trial.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:4

    The aim of this study was to evaluate the effectiveness of oral n-acetyl cysteine, as a potential nephroprotective agent, in preventing and/or attenuating amphotericin B-induced electrolytes imbalances.. During a one year period, patients were to receive conventional amphotericin b for any indication for at least one week and were randomly allocated to receive either placebo or 600 mg oral n-acetyl cysteine twice daily during the treatment course of amphotericin b. Demographic and clinical data of the study population were gathered. Different aspects of amphotericin b nephrotoxicity including decrease of glomerular filtration rate, hypokalemia, hypomagnesemia, renal magnesium and potassium wasting were assessed. Each patient was monitored for any adverse reaction to n-acetyl cysteine. Sixteen and 14 patients in the n-acetyl cysteine and placebo groups completed the study, 3incidences of hypokalemia (75 % versus 70 %; P = 0.724) and hypomagnesemia (30 % versus 20 %; P = 0.468) did not differ significantly between placebo and NAC groups, respectively. Although the rate of AmB nephrotoxicity was higher in the placebo than in the NAC group (60 % versus 40 %), this difference was not statistically significant (P = 0.209) even after adjusting for probable associated factors of amphotericin b nephrotoxicity (P = 0.206). The incidence as well as time of onset of electrolyte abnormalities also did not differ significantly between placebo and n-acetyl cysteine groups. About 44 % of n-acetyl cysteine recipients experienced new onset nausea and a mild unpleasant taste during the study.. Oral n-acetyl cysteine during the amphotericin B treatment course was not significantly effective in preventing or mitigating different features of its nephrotoxicity including decrease of glomerular filtration rate, hypokalemia, hypomagnesemia, and renal potassium as well as magnesium wasting.

    Topics: Acetylcysteine; Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Male; Water-Electrolyte Imbalance; Young Adult

2014

Other Studies

1 other study(ies) available for amphotericin-b and Water-Electrolyte-Imbalance

ArticleYear
A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology.
    British journal of haematology, 1998, Volume: 103, Issue:1

    No comparative clinical information on the properties of lipid-associated amphotericin preparations is presently available. In this single-centre retrospective analysis over a 5-year period the indications, efficacy and toxicity of true liposomal amphotericin (AmBisome) were compared with a lipid complexed preparation (Abelcet). In a novel approach APACHE III scores were used in addition to neutrophil counts, disease status and additional immunosuppression to accurately assess the severity of illness in both groups and enable valid comparison. Overall, AmBisome at a median dose of 1.9 mg/kg/d was found to have similar clinical outcome to Abelcet at a median dose of 4.8 mg/kg/d. Nephrotoxicity and electrolyte abnormalities were similar in both groups. Rigors and febrile episodes were more common with Abelcet. Prospective randomized comparative trials are required to clarify the optimum dosages and therapeutic and economic issues associated with these agents.

    Topics: Adult; Amphotericin B; Antifungal Agents; Creatinine; Drug Combinations; Female; Hematologic Neoplasms; Humans; Immune Tolerance; Leukocyte Count; Male; Mycoses; Neutrophils; Opportunistic Infections; Phosphatidylcholines; Phosphatidylglycerols; Retrospective Studies; Treatment Outcome; Water-Electrolyte Imbalance

1998